Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymosin alpha-1.

C D Ancell1, J Phipps, L Young

  • 1Nova Factor, Memphis, TN, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|May 31, 2001
PubMed
Summary

Thymosin alpha-1 (TA1) shows potential for treating Hepatitis B as monotherapy and Hepatitis C in combination with interferon alfa-2b. Clinical trial results for TA1 in viral hepatitis have been mixed, with further research needed on long-term outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonemergency colectomy for inflammatory bowel disease: the National Consultant Information Programme (NCIP) used to highlight colorectal surgery practice and outcomes in England 2018-2022.

Annals of the Royal College of Surgeons of England·2025
Same author

Motion onset VEPs can see through the blur.

Scientific reports·2024
Same author

Local Anaesthesia for Enzymatic Debridement of Cutaneous Burns: A Prospective Analysis of 27 Cases.

Annals of burns and fire disasters·2024
Same author

Influence of Selective Carbon 1s Excitation on Auger-Meitner Decay in the ESCA Molecule.

The journal of physical chemistry letters·2024
Same author

Hashimoto's thyroiditis and renal transplant rejection.

Journal of endocrinological investigation·2023
Same author

CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity.

Heliyon·2023

Area of Science:

  • Immunology
  • Pharmacology
  • Hepatology

Background:

  • Thymosin alpha-1 (TA1) is a synthetic polypeptide with immunomodulatory properties.
  • TA1 is being investigated for its potential in treating viral hepatitis and other conditions like malignant melanoma and DiGeorge's syndrome.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of thymosin alpha-1 (TA1).
  • To evaluate the potential of TA1 as a therapeutic agent for Hepatitis B and Hepatitis C.

Main Methods:

  • Review of existing literature on TA1, including pharmacology, pharmacokinetics, and clinical trial data.
  • Analysis of clinical trial results for TA1 in patients with Hepatitis B and Hepatitis C, including comparisons with standard treatments like interferon alfa-2b.

Main Results:

  • TA1 demonstrated mixed efficacy in Hepatitis B trials, with some studies showing viral DNA clearance.
  • In Hepatitis C trials, combination therapy with TA1 and interferon alfa-2b showed improved outcomes in normalizing ALT levels and viral RNA clearance compared to interferon alfa-2b alone.
  • TA1 was generally well-tolerated, with most adverse effects being local irritation at the injection site.

Conclusions:

  • TA1 may hold promise as monotherapy for Hepatitis B and as an adjunct to interferon alfa-2b for Hepatitis C.
  • Further research is required to ascertain the long-term effects of TA1 on morbidity and mortality in patients with chronic viral hepatitis.

Related Experiment Videos